Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results
Journal of the European Academy of Dermatology and Venereology · 2025-12 · 39 (12) · 2056-2068
DOI: 10.1111/jdv.20674 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 03.04.2025. Verfasst von Lian F van der Gang und 22 weiteren Autor:innen. Beteiligte Einrichtung: National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlan…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Biological Products, Infections. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice.
Objectives
To assess the differential infection risk of biologic and JAKi treatment in patients with moderate‐to‐severe AD in a real‐world setting.
Methods
This prospective, multicentre study evaluated treatment‐emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient‐years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio‐/JAKi‐naïve patients.
Results
In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4–65.5/100 PY) compared to biologics (13.6–22.0), especially for herpes infections ( n = 195, 24.6%; JAKi 13.6–19.8 vs. biologicals 3.0–3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1–5.5; baricitinib HR 4.2, 95% CI: 2.9–6.2; upadacitinib HR 4.0, 95% CI: 3.2–5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0–2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4–2.6, p < 0.0001; 2.4, 1.3–4.4, p = 0.003, resp.), was identified as an independent factor associated with infection.
Conclusions
This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate‐to‐severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient‐specific risks such as prior skin infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Dermatology, Reinier de Graaf Hospital, Delft, The Netherlands.
- Department of Dermatology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
ORCID-Profile: Lian F van der Gang, Celeste M Boesjes, Laura Loman, Antoni Gostynksi
Zitieren
APA
van der Gang, L. F., Atash, K., Zuithoff, N. P. A., Haeck, I., Boesjes, C. M., Bacoş-Cosma, O. I., Loman, L., Kamsteeg, M., Stadhouders-Keet, S., Oosting, A. J., van Lynden-van Nes, A. M. T., Politiek, K., Gostynksi, A., Berntsen-Zandbergen, L., Christoffers, W. A., Flinterman, A., Touwslager, W. R. H., Velstra, B., Stewart, S. M., …, & de Bruin-Weller, M. S. (2025). Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. Journal of the European Academy of Dermatology and Venereology, 39(12), 2056-2068. https://doi.org/10.1111/jdv.20674
Vancouver
van der Gang LF, Atash K, Zuithoff NPA, Haeck I, Boesjes CM, Bacoş-Cosma OI, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. Journal of the European Academy of Dermatology and Venereology. 2025;39(12):2056-2068. doi:10.1111/jdv.20674
BibTeX
@article{vanderGang2025,
author = {van der Gang, Lian F and Atash, Keneshka and Zuithoff, Nicolaas P A and Haeck, Inge and Boesjes, Celeste M and Bacoş-Cosma, Octavian I and Loman, Laura and Kamsteeg, Marijke and Stadhouders-Keet, Simone and Oosting, Albert J and van Lynden-van Nes, Anneke M T and Politiek, Klaziena and Gostynksi, Antoni and Berntsen-Zandbergen, Lisette and Christoffers, Wianda A and Flinterman, Annebeth and Touwslager, Wouter R H and Velstra, Berit and Stewart, Shiarra M and van Erp, Francine C and de Graaf, Marlies and Schuttelaar, Marie-Louise A and de Bruin-Weller, Marjolein S},
title = {Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {12},
pages = {2056--2068},
doi = {10.1111/jdv.20674}
}
EUVIMED